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Introduction
Platelet aggregation is a crucial event in the development of arterial thrombosis and is mediated by the binding of fibrinogen to activated integrin a IIb b 3 receptors on the surface of platelets. Platelet activation and aggregation can be blocked by nitric oxide (NO) (1, 2) . NO is derived either from endothelial cells or platelets (3) and activates soluble NO-sensitive guanylyl cyclase (sGC) resulting in the production of cGMP (4) . The main targets of cGMP in platelets are cGMP-dependent protein kinase Ib (cGKI) as well as cGMP-regulated PDEs 2, 3 and 5 (5, 6) . Data from human (7) and mouse (8) cGKI-deficient platelets suggest that cGKI is an important mediator of NO/cGMP effects in platelets. For example, in vivo studies of the micorcirculation after ischemia/reperfusion in cGKI-deficient mice clearly showed that cGKI prevents intravascular platelet aggregation (8) .
Recently, the small guanine-nucleotide-binding protein Rap1 has attracted a lot of interest as major regulator of integrin activity (9) (10) (11) (12) . Rap1A and B isoforms have been described exhibiting 95 % sequence identity and platelets express particularly high levels of Rap1B (13) (14) (15) . Rap1 efficiently activates various integrins including the platelet integrin a IIb b 3 , which mediates fibrinogen binding required for platelet aggregation (16, 17) . Very recently, deletion of mouse CalDAG-GEFI (also known as RasGRP2), a guanine-nucleotide-exchange factor (GEF) involved in the activation of Rap1, was shown to result in reduced platelet aggregation and increased bleeding time (18) . Rap1 is a common target of many different activation pathways in platelets. ADP, thrombin, collagen, epinephrine and platelet-activating factor induce Rap1-GTP formation (19) . The pathways leading to Rap1 activation in platelets are controversial. For example, ADP has been suggested to activate Rap1 by Ca 2+ -dependent (19, 20) as well as Ca 2+ -independent mechanisms involving the Ga i -coupled P2Y 12 receptor (21, 22) . Recently, phosphatidylinositol 3-kinase (PI3K) was reported to mediate Rap1 activation by different platelet agonists (22) (23) (24) . In megakaryocytes (platelet progenitors) turbulence activates Rap1 by a yet undefined mechanism independent of PLC, PKC, Ca 2+ , PI3K and actin dynamics (17) .
Rap1A and B are known to be phosphorylated by cyclic nucleotide-regulated kinases and the platelet isoform Rap1B was reported to be the preferred substrate for these kinases (13, 25, 26) . However, Rap1B phosphorylation has a slow time course and does not affect GTPbinding or GTPase activity of Rap1 (25, 27) . In the present study we have investigated possible effects of NO on stimulus-induced Rap1 activation. We show that NO inhibits Rap1-GTP formation in human platelets. Since Rap1 is an important regulator of integrin function and platelet aggregation, we suggest that NO-induced Rap1 inhibition might be resposible for the strong anti-aggregatory function of NO. Furthermore, we show that NO effects on Rap1 involve cGMP as well as cGKI. We also provide initial data on the possible mechanisms involved in Rap1 inhibition.
Materials and Methods

Reagents
Human thrombin, ADP, rat collagen I, YC-1, ODQ and MRS2179 were obtained from Sigma.
DEA-NOate and DETA-NOate were purchased from ALEXIS Biochemicals. 8pCPT-cGMP and Rp-8pCPT-cGMPS were from Biolog. Polyclonal antibody against Rap1 (sc-65) was from Santa Cruz Biotechnology. Antibodies against P-VASP serine 239 (16C2) and cGKI have been described previously (28, 29) . HRP-coupled goat-anti-rabbit and goat-anti-mouse were from Dianova. GSH Sepharose 4B was from Amersham Biosciences. cDNA for the GST-Rap-binding domain (RBD) of the Ral guanine nucleotide dissociation stimulator was kindly provided by Johannes L. Bos (Utrecht). 
Platelet preparation
Infection of MEG-01 cells
MEG-01 megakaryocytes were obtained from ATCC and cultured in RPMI1640 medium supplemented with 20% heat-inactivated fetal calf serum and penicillin and streptomycin.
cDNAs for wild-type cGKIb or a catalytically inactive mutant, cGKIb-K405A under control of a CMV-promoter, were transfected into MEG-01 cells using adenoviral vectors as described (29) . For infection cells were incubated with 1x10 10 virus particles/ml for 2 hours in serum-free medium followed by addition of complete medium for 24 hours.
Rap1-GTP assay in platelets and MEG-01 cells
Washed platelets (aliquots of 500 µl) were equilibrated to 37°C in a waterbath for 10 min Rap1-GTP assays in megakaryocytes were performed two days after adenoviral infection. 24
houres before the assay MEG-01 cells were incubated overnight in serum-free medium. The next day cells were resuspended at 20x10 6 cells/ml in medium. 500 µl aliquots of cell suspension in 1.5 ml tubes were incubated for 30 min at 37°C, then samples were mixed by inverting tubes 5 times up and down followed by 2 min rest at 37°C. Reactions were terminated by adding 500 µl of 2-fold lysis buffer as described above.
Platelets and MEG-01 cells were lysed and insoluble material was pelleted. Samples of 50 µl
were removed for analysis of total Rap1, cGKI and phosphorylated VASP. 75 µl of a 10% 
Results
NO inhibits Rap1 activation
To characterize the effects of NO/cGMP on Rap1 activity we used a pull-down assay specific for active Rap1 developed by the group of J. Bos (19) . In this assay the Ras binding domain of RalGDS fused to GST is used as a specific probe for active Rap1-GTP. In our studies we used washed platelets and Rap1 activation was induced by thrombin, ADP and collagen. NO effects depend, at least in part, on the type of NO-donor used (30) . For this reason we chose two NONOate molecules with different NO liberation properties as NO-donors: DEA-NO, which has a half-life of 2 min at 37°C and the slow-releasing substance DETA-NO (t 1/2 =20h).
DEA-NO (Fig. 1A) as well as DETA-NO (not shown) inhibited thrombin-induced formation of Rap1-GTP. Furthermore, ADP-and collagen-induced Rap1 activation were inhibited by NO-donors (Figs. 1B, C and Fig. 4) . Treatment of platelets with DETA-NO alone had no effect on basal Rap1 activity (Fig. 1B, lanes 2-4) .
NO effects are mediated by cGMP
An important target of NO in platelets is the cGMP generating enzyme sGC. To verify a role for sGC in NO-induced Rap1 inhibition we used YC-1, an NO-independent activator of sGC 2C ). In parallel we analyzed the phosphorylation state of VASP, an actin and focal adhesion binding protein and established substrate of cGKI in platelets (28, 29) . For this purpose we used a previously described phosphorylation specific antibody (28) . YC-1-and DETAinduced reduction of Rap1-GTP levels correlated with increased VASP phosphorylation, i.e.
increased cGKI activity (Fig. 2) .
cGMP effects are mediated by cGKI
To further evaluate if cGKI can mediate cGMP effects on Rap1 activity we used the membrane-permeable cGMP-analog 8pCPT-cGMP. Increasing concentrations of 8-pCPTcGMP strongly reduced Rap1-GTP levels independently of the platelet agonists used for Rap1 activation including thrombin, ADP and collagen I (Fig. 3) . As shown before in Fig. 2 activation of cGKI also resulted in the phosphorylation of VASP and the amount of VASP phosphorylation correlated with the decrease in Rap1-GTP.
To provide further evidence that cGKI was mediating NO effects we inhibited cGKI function with Rp-8pCPT-cGMPS in the presence of the NO-donor DEA-NO. As shown before (Fig. 1) DEA-NO reduced Rap1-GTP levels (Fig. 4, middle lanes) . The cGKI inhibitor Rp-8pCPT-cGMPS abrogated NO effects indicating that cGKI was involved in NO-induced Rap1 inhibition (Fig. 4, right lanes) . Rp-8pCPT-cGMPS alone did not affect ADP-and thrombininduced formation of Rap1-GTP (data not shown).
cGKI inhibits Ca
2+
-independent activation of Rap1
NO/cGMP/cGKI is known to inhibit platelet signalling by inhibition of Ca 2+ release from intracellular stores (32) . Also, the Ca 2+ -dependent Rap1-GEF CalDAG-GEFI/RasGRP2 has been found in mouse platelets (18 (Fig. 5A ). This concentration of MRS2179 corresponds to the amount necessary to block mobilization of intracellular Ca 2+ stores in platelets completely (34) . Consequently, the remaining ADP-induced Rap1 activation is mediated exclusively by Ga i -coupled pathways. Addition of the cGKI activator 8-pCPT-cGMP in the presence of MRS2179 further reduced the level of Rap1-GTP ( Fig. 5B and 5C ). From these experiments we conclude that Rap1 activation in platelets requires Ca 2+ -dependent as well as Ca 2+ -independent signals. Secondly, cGKI can inhibit Ga i -mediated Ca 2+ -independent Rap1 activation.
cGKI inhibits turbulence-induced Rap1 activation in megakaryocytes
To gain further insight into the mechanisms involved in NO/cGMP/cGKI-induced Rap1 inhibition we studied Rap1 regulation in megakaryocytes, i.e platelet progenitor cells. Rap1 has been shown to be activated by turbulence in MEG-01 megakaryocytes (17) . Rap1 activation ocurred independently of PLC-, PKC-, Ca 2+ -and PI3K-signalling as well as actin dynamics in these cells (17) . Because MEG-01 cells do not express detectable amounts of endogenous cGKI (Fig. 6, middle) , we introduced wild-type cGKI as well as a catalytically inactive control mutant into MEG-01 cells using adenoviral vectors. The inactive cGKI bears a point mutation of an essential lysine in the catalytic site (29) . Wildtype cGKI inhibited turbulence-induced Rap1 activation in MEG-01 cells (Fig. 6 ). The catalytically inactive mutant cGKI was incapable of mediating this effect.
Discussion
In the present study we show that Rap1 activation in human platelets is regulated by NO via cGMP and cGKI. Different components of the NO/cGMP pathway including NO, specific activators of sGC and cGKI-specific cGMP analogs all consistently inhibited the formation of Rap1-GTP. Furthermore, NO/cGMP effects were independent of the platelet agonists used for Rap1 activation. Rap1 is an important switch controlling the activity of the platelet fibrinogen receptor (integrin a IIb b 3 ), which is required for platelet aggregation (9, 11, 16, 17) . Thus regulation of Rap1 might contribute to the potent anti-aggregatory actions of NO, cGMP and cGKI. Many reports in the literature have postulated autocrine effects of platelet-derived NO on platelet aggregation (3, (35) (36) (37) . In the present work Rap inhibition depended on exogenously added activators of the NO/cGMP pathway. Also, inhibition of cGMP production by ODQ in the absence of NO-donors, did not reveal any basal inhibitory activity towards Rap1 (Fig. 2C) We therefore conclude that inhibition of Rap1 in vivo depends on endothelium-derived NO.
Our study provides evidence that cGKI is the mediator of NO/cGMP effects on Rap1. We used a number of different approaches to verify the role of cGKI including specific activators and inhibitors of cGKI as well as transfection of cGKI into cGKI-deficient cells. In addition we analyzed the phosphorylation of VASP as a measure of cGKI kinase activity. All these different approaches yielded consistent data regarding the role of cGKI. Furthermore, in all our experiments only inhibitory actions of NO/cGMP/cGKI on platelet Rap1 activation were observed. Also basal Rap1GTP levels were not elevated by NO/cGMP. cGMP and cGKI have been proposed to enhance platelet activation and aggregation under certain conditions (38, 39) . However, these data were challenged by others (40, 41) . The controversial data might result from unexpected side-effects of cGMP-analogs. For example, Rp-8pCPT-cGMPS was shown to inhibit thrombin-induced P-selectin expression as well as Ca 2+ -mobilization independently of cGKI and without any effects on VASP phosphorylation (40) . These cGKIindependent side-effects of Rp-8pCPT-cGMPS were evident particularly after short-term application of the cGMP-analog (1 min). In our experiments (Fig. 4 ) platelets were preincubated with Rp-8pCPT-cGMPS for 15 min and we never observed any inhibitory effects of Rp-8pCPT-cGMPS on ADP-or thrombin-induced Rap1-GTP formation.
Furthermore, possible side-effects of Rp-8pCPT-cGMPS might not affect Rap1 activation pathways.
Conflicting results have been presented regarding the role of intracellular Ca 2+ -release for Rap1 activation. Rap1 activation was initially considered to be Ca 2+ -and PKC-mediated (19, 20) . Later studies on ADP-induced Rap1 activation suggested either a completely Ca 2+ -independent Rap1 activation mediated by the Ga i -coupled P2Y 12 receptor and PI3K (21, 24) , or a mixture of P2Y 12 -and P2Y 1 -mediated mechanisms (22) . Our study supports the notion that both, Ca 2+ -dependent Ga q -mediated (P2Y 1 ) and Ga i -mediated (P2Y 12 ) pathways, are involved in ADP-induced Rap1 activation in human platelets (Fig. 7) . Our data imply a relative contribution of 70 % Ga q -mediated versus 30 % Ga i -mediated signals to the activation of Rap1 (Fig. 5C) . However, the role of Ga q -and Ga i -mediated signals for Rap1 activation is probably more complex. For example, AR-C69931MX, a specific P2Y 12 receptor antagonist, can inhibit the P2Y 1 -induced calcium response (42) suggesting that G i -mediated pathways contribute to Ga q -mediated calcium signalling. On the other hand, Ga q (P2Y 1 )
probably contributes to Ga i -signalling (P2Y 12 ) since AR-C69931MX alone is capable of blocking ADP-induced Rap1 activation completely (21) . cGKI is known to inhibit Ca 2+ -dependent platelet responses (32) . However, our study as well as data by others (43) suggest that cGKI also inhibits Ca 2+ -independent signalling.
A remaining open question is the identity of the cGKI substrate(s) mediating Rap1 inhibition.
Early studies showed direct phosphorylation of Rap1 by cGKI (25, 26) . However, Rap1
phosphorylation did not change its GTP-binding or GTPase activity (25) . Furthermore, the slow kinetics of Rap1 phosphorylation do not correlate with the fast inhibition of platelet activation by NO/cGMP (44) . The cGKI substrate VASP has been shown to be involved in platelet adhesion (45) , however, NO/cGMP effects on platelet aggregation were only marginally affected in VASP-deficient mice (46, 47) . Very recently, RIAM was identified, a new cytoskeletal protein capable of binding both Rap1 and VASP (48) . However, in this paper no effect of VASP on Rap1 activity was described and RIAM expression in platelets was not investigated. Other known substrates of platelet cGKI include PDE5, which mediates negative feedback regulation of cGMP levels (49) and LASP and HSP27, two actin-binding proteins without any known integrin regulating functions (50, 51) . In our study NO/cGMP inhibited Rap1 activation induced by many different stimuli. We conclude that the most likely target of NO/cGMP/cGKI should be a molecule common to these different signalling pathways. Possible candidates are the guanine-nucleotide exchange factors (GEFs) or GTPase activating proteins (GAPs) required for Rap1 function (Fig. 7) . Many specific GEFs and GAPs for Rap1 have been identified (9) , however, until now only CalDAG-GEFI/RasGRP2 expression has been demonstrated in mouse platelets (18) . Washed platelets were treated with 200 µM Rp-8pCPT-cGMPS for 15 min, then 1 µM DEA-NO was added for 1 min followed by 10 µM ADP for various time-points. Rap1-GTP and total Rap1 were analyzed as described. Blots from three independent pull-down experiments were scanned and quantified. Shown are means + SEM. The amount of Rap1-GTP generated by incubation with ADP alone for 15 sec. was set to 100 %. Then 10 µM ADP was applied for 1 min, cells were lysed and pull-down assays were performed with the activation specific probe for Rap1 as well as control Western blots for total Rap1 and phosphorylated VASP. Blots from three independent pull-down experiments were scanned and quantified (panel C). Shown are means + SEM. The amount of Rap1-GTP generated by incubation with ADP alone was set to 100 %. Human MEG-01 megakaryocytes were infected with adenoviral vectors for either wildtype or catalytically inactive cGKIb. Two days after infection cells were subjected to mixing-induced turbulence followed by 2 min rest. Then cells were lysed and levels of Rap1-GTP were determined by pull-down assay, cGKI expression as well as the phosphorylation state of
